PharmaCyte Biotech Net Income Over Time
| PMCB Stock | USD 0.82 0 0.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PharmaCyte Biotech Performance and PharmaCyte Biotech Correlation. PharmaCyte | Build AI portfolio with PharmaCyte Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. Anticipated expansion of PharmaCyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PharmaCyte Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding PharmaCyte Biotech requires distinguishing between market price and book value, where the latter reflects PharmaCyte's accounting equity. The concept of intrinsic value—what PharmaCyte Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push PharmaCyte Biotech's price substantially above or below its fundamental value.
It's important to distinguish between PharmaCyte Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PharmaCyte Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, PharmaCyte Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare PharmaCyte Biotech and related stocks such as Radiopharm Theranostics, Quoin Pharmaceuticals, and NovaBay Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNRX | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | 15.3 M | 10.2 M | 15.3 M | (1.6 M) | (2.1 M) | (21.5 M) | (9.4 M) | (8.7 M) | (9 M) | (8.1 M) | (7.7 M) |
| NBY | (977 K) | (5.1 M) | (7 M) | (16 M) | (15.2 M) | (19 M) | (13.2 M) | (7.4 M) | (6.5 M) | (9.7 M) | (11 M) | (5.8 M) | (10.6 M) | (9.6 M) | (7.2 M) | (6.5 M) | (6.8 M) |
| TCRT | (72.5 K) | (63.8 M) | (96.1 M) | (57.1 M) | (31.8 M) | (120.1 M) | (165.3 M) | (54.3 M) | (53.1 M) | (117.8 M) | (78.8 M) | (78.8 M) | (37.7 M) | (35.1 M) | (4.7 M) | (4.2 M) | (4.4 M) |
| VIVS | (147.8 K) | (43.6 M) | (43.6 M) | (25.8 M) | (30.1 M) | (38.6 M) | (38.4 M) | (34.8 M) | (26.6 M) | (18.7 M) | (16.8 M) | (11.4 M) | (17.3 M) | (14.7 M) | (2.5 M) | (2.9 M) | (3 M) |
| IBO | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (98.1 K) | (590.1 K) | (760.1 K) | (3.9 M) | (7.1 M) | (4.3 M) | (2.1 M) | (1.8 M) | (1.9 M) |
| KTTA | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (2.2 M) | (13.9 M) | (16 M) | (13.9 M) | (12.5 M) | (13.1 M) |
| PLRZ | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (73 K) | (711 K) | (779 K) | (600 K) | (1.5 M) | (1.4 M) | (1.3 M) |
| CYCN | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (93.9 M) | (115.3 M) | (123 M) | (77.8 M) | (51.6 M) | (44.1 M) | (5.3 M) | (3.1 M) | (3.5 M) | (3.7 M) |
| BCLI | (25.6 K) | (3.9 M) | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (23.7 M) | (17.2 M) | 11.6 M | 10.5 M | 11 M |
PharmaCyte Biotech and related stocks such as Radiopharm Theranostics, Quoin Pharmaceuticals, and NovaBay Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in PharmaCyte Biotech financial statement analysis. It represents the amount of money remaining after all of PharmaCyte Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| PharmaCyte Biotech | PMCB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3960 Howard Hughes |
| Exchange | NASDAQ Exchange |
USD 0.819
Check out PharmaCyte Biotech Performance and PharmaCyte Biotech Correlation. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.